Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing c
(Financial Post, 2025-10-27T21:48:14Z)